Lone Star Funds

lonestarfunds.com

Lone Star Funds, legally known as Lone Star Global Acquisitions Ltd., is a global private equity firm founded in 1995 by John Grayken and headquartered in London, UK. With approximately $96 billion in aggregate capital commitments across 26 funds, the firm invests in private equity, credit, and real estate, targeting complex opportunities worldwide through offices in North America, Europe, the Middle East, and Asia Pacific.

Read more

In the chemical industry, Lone Star has built a platform in high-performance polymers and specialty chemicals. Recent transactions include the 2026 completion of the acquisition of RadiciGroup's High Performance Polymers and Specialty Chemicals businesses—producers of polyamide polymers and chemical intermediates for automotive, electronics, consumer goods, and industrial applications—and binding agreements to acquire DOMO Engineered Materials, featuring the TECHNYL® brand of polyamide compounds (PA6 and PA66). These deals create a global tier-1 compounder with expanded geographic footprint across Europe, Asia, and the US, and enhanced capabilities in recycled and bio-based solutions. Jochen Fabritius leads the combined organization as CEO.

Also known as LONE STAR GLOBAL ACQUISITIONS, LTD..

Projects Lone Star Funds is involved in

None yet. When a new project in the record names Lone Star Funds as owner, partner or investor, it shows here.

Active projects close to Lone Star Funds

Lone Star Funds in chemical industry news

12 May 2026
DOMO Engineered Materials joins RadiciGroup to create global tier‑1 compounder

Acquisition closed; combined global tier‑1 compounding platform serving diverse end markets. TECHNYL brand and teams remain; CEO appointed; focus on innovation and sustainability.

4 May 2026
DOMO Engineered Materials acquired by Lone Star Funds; TECHNYL® included

Fund affiliate buys engineered materials unit: three EU plants, global subsidiaries, IP/brand, sales, application center and masterbatch ops; Belle Étoile excluded; leadership continuity planned.